Comparison of the efficacy between sequential therapy with teriparatide and denosumab and denosumab monotherapy in suppressing fragility fracture risk | SpringerLink
FRAME Study: The Foundation Effect of Building Bone With 1 Year of Romosozumab Leads to Continued Lower Fracture Risk After Transition to Denosumab - Cosman - 2018 - Journal of Bone and
Treatment Sequences with Romosozumab Before or After Antiresorptive Medication - ACR Meeting Abstracts
Effects of denosumab followed by zoledronate on BMD in postmenopausal... | Download Scientific Diagram
WO2013181575A2 - Methods related to denosumab - Google Patents
Frontiers | Pros and Cons of Denosumab Treatment for Osteoporosis and Implication for RANKL Aptamer Therapy
Frontiers | Current comprehensive understanding of denosumab (the RANKL neutralizing antibody) in the treatment of bone metastasis of malignant tumors, including pharmacological mechanism and clinical trials
Prolia® (denosumab) DAPS Study Design | Prolia®
Prolia, INN-denosumab
Frontiers | A Multi-Institutional Randomized Controlled Trial to Investigate Whether Zoledronate Prevents Bone Loss After Discontinuation of Denosumab: The Study Protocol of Denosumab Sequential Therapy (DST) Trial
Figures and data in Modeling osteoporosis to design and optimize pharmacological therapies comprising multiple drug types | eLife
Adherence, Preference, & Satisfaction Study | Prolia® (denosumab)
Denosumab in the Treatment of Osteoporosis: 10 Years Later: A Narrative Review | SpringerLink
Carboxy Terminal Telopeptide - an overview | ScienceDirect Topics
DB06643 Denosumab C6404H9912N1724O2004S kDa CATEGORY - ppt download
Denosumab mimics the natural decoy receptor osteoprotegerin by interacting with its major binding site on RANKL | Oncotarget
The effect of osteoporosis treatment on bone mass - ScienceDirect
Sequencing Osteoporosis Therapies
Denosumab in the Treatment of Osteoporosis: 10 Years Later: A Narrative Review | SpringerLink
Long-term follow up after denosumab treatment for osteoporosis – rebound associated with hypercalcemia, parathyroid hyperplasia, severe bone mineral density loss, and multiple fractures: a case report | Journal of Medical Case Reports
Denosumab – die reversible Wirksamkeit im klinischen Fokus Denosumab – the reversible efficacy in the clinical focus
JCM | Free Full-Text | Denosumab Discontinuation and the Rebound Phenomenon: A Narrative Review
